Kathleen Potter

Dr. Kathleen Potter


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2002 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
KPKathleen Potter
Kathleen Potter
PHPaul Hobby
Paul Hobby
SKSusanne Klijn
Susanne Klijn
FSFreda K. Stevenson
Freda K. Stevenson
BSBrian J. Sutton
Brian J. Sutton
The monoclonal IgM cold agglutinins that bind to the I/i carbohydrate Ags on the surface of RBCs all have Ig H chains encoded by the V4-34 gene segment. This mandatory use indicates that distinctive amino acid sequences may be involved in recognition. Critical amino acids exist in framework region 1 (FR1) of V4-34-encoded Ig, and these generate a specific Id determinant which apparently lies close to the I binding site. However, I binding by Id-expressing Ig can be modulated by sequences in complementarity-determining region (CDR)H3. Examination of the crystal structure of an anti-I cold agglutinin has revealed a hydrophobic patch in FR1 involving residue W7 on β-strand A and the AVY motif (residues 23–25) on β-strand B. In this study we used mutagenesis to show that each of the strand components of the hydrophobic patch is required for binding the I carbohydrate Ag. In addition, the crystal structure reveals that amino acids in the carboxyl-terminal region of CDRH3 form a surface region adjacent to the hydrophobic patch. We propose that the I carbohydrate Ag interacts simultaneously with the entire hydrophobic patch in FR1 and with the outside surface of CDRH3. This interaction could leave most of the conventional binding site available for binding other Ags.

15 April 2003 in Blood
Verified
Journal Article
Closed access
PDF file
KPKathleen Potter
Kathleen Potter
JOJenny Orchard
Jenny Orchard
ECEustacia Critchley
Eustacia Critchley
CMC. Ian Mockridge
C. Ian Mockridge
AJAnnette Jose
Annette Jose
FSFreda K. Stevenson
Freda K. Stevenson
Chronic lymphocytic leukemia (CLL) comprises 2 subsets, distinguished by expression of unmutated or mutated VHgenes, with the former having a worse prognosis. Biased usage of the V1-69 gene is found in unmutated cases and is combined with selected D gene segments and JH6. It is controversial whether this is a CLL-associated feature or mirrors the normal B-cell pattern. Since CLL is a disease of the elderly, where changes in the B-cell repertoire may occur, we have analyzedV1-69 usage in the elderly (older than 75 years) population. Using monoclonal antibody (MoAb) G6, specific for 51p1-related V1-69 alleles, we found no increased expression with age. In 51p1-encoded immunoglobulin M (IgM), complementarity-determining region 3 (CDR3) length and frequency of D and JH genes were similar to those in the healthy young and distinct from those in CLL. These findings support the concept that CLL arises from B cells driven by antigen/superantigen and is not a stochastic event in the elderly B-cell population.

15 March 2006 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KPKathleen Potter
Kathleen Potter
CMC. Ian Mockridge
C. Ian Mockridge
LNLouise Neville
Louise Neville
IWIsla Wheatley
Isla Wheatley
MSMichael Schenk
Michael Schenk
FSFreda K. Stevenson
Freda K. Stevenson
Purpose: To determine the origin and relationship of the rare IgG+ variant of chronic lymphocytic leukemia (CLL) to the two common IgM+IgD+ subsets that are distinguished by expression of unmutated or mutated VH genes, with the former having a worse prognosis. Experimental Design: IgG+ CLL cells were characterized using phenotypic, functional, and immunogenetic analyses. Results: IgG+ CLL was phenotypically similar to mutated IgM+IgD+ CLL (M-CLL) and variably expressed CD38 (4 of 14). ZAP-70, a tyrosine kinase preferentially expressed in unmutated CLL, was found in only 2 of 14 cases. The ability to signal via surface IgM (sIgM) varies between the main subsets of CLL and is associated with expression of ZAP-70. In IgG+ CLL, 9 of 14 responded to engagement of sIgG with no apparent requirement for expression of CD38 or ZAP-70. However, signal capacity correlated with intensity of sIgG expression. Most switched immunoglobulin variable region genes were somatically mutated without intraclonal variation, and no case expressed activation-induced cytidine deaminase. Derivation from a postgerminal center B cell is, therefore, likely, and a relationship with M-CLL is suggested. This is supported by a shared biased usage of the V4-34 gene. Similar bias in normal B cells developed with age, providing an expanded population for transforming events. However, conserved sequences detected in the CDR3 of V4-34-encoded γ chains were not found M-CLL, indicating no direct path of isotype switch from M-CLL. Conclusion: IgG+ CLL is likely to arise from an age-related expanded pool of B cells, on a path parallel to M-CLL, and perhaps with a similar clinical course.

1 December 2002 in Lupus
Verified
Journal Article
Closed access
KPKathleen Potter
Kathleen Potter
CMC I Mockridge
C I Mockridge
ARA Rahman
A Rahman
SBS Buchan
S Buchan
THT Hamblin
T Hamblin
FSF K Stevenson
F K Stevenson
A variety of cell surface markers are being used to identify B cell subpopulations in peripheral blood. Currently at least eight subpopulationshave been identified. Analyses of healthy individuals indicate that in general the various B cell subpopulations exist in relatively similar ratios in unrelated individuals. It has been demonstrated that B lymphocyte homeostasis is disturbed during infection and autoimmune disease. In this review we compare the distribution of B cell subpopulations in the peripheral blood of patients with systemic lupus erythematosus, rheumatoid arthritis and primary Sjogren's syndrome with each other, and with healthy individuals. The different autoimmune diseases have distinct changes in the B cell subpopulations. Understanding the nature of these B subpopulation signatures will potentially impact understanding the mechanisms of disease, diagnosis and therapy.

22 March 2018 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
BZBashar Zeidan
Bashar Zeidan
AMAntigoni Manousopoulou
Antigoni Manousopoulou
DGDiana J. Garay-Baquero
Diana J. Garay-Baquero
CWCory White
Cory White
SLSamantha E. T. Larkin
Samantha E. T. Larkin
Spiros GarbisSpiros Garbis
Spiros Garbis
Early-onset breast cancer (EOBC) affects about one in 300 women aged 40 years or younger and is associated with worse outcomes than later onset breast cancer. This study explored novel serum proteins as surrogate markers of prognosis in patients with EOBC. Serum samples from EOBC patients (stages 1–3) were analysed using agnostic high-precision quantitative proteomics. Patients received anthracycline-based chemotherapy. The discovery cohort (n = 399) either had more than 5-year disease-free survival (DFS) (good outcome group, n = 203) or DFS of less than 2 years (poor outcome group, n = 196). Expressed proteins were assessed for differential expression between the two groups. Bioinformatics pathway and network analysis in combination with literature research were used to determine clinically relevant proteins. ELISA analysis against an independent sample set from the Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) cohort (n = 181) was used to validate expression levels of the selected target. Linear and generalized linear modelling was applied to determine the effect of target markers, body mass index (BMI), lymph node involvement (LN), oestrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor 2 status on patients’ outcome. A total of 5346 unique proteins were analysed (peptide FDR p ≤ 0.05). Of these, 812 were differentially expressed in the good vs poor outcome groups and showed significant enrichment for the insulin signalling (p = 0.01) and the glycolysis/gluconeogenesis (p = 0.01) pathways. These proteins further correlated with interaction networks involving glucose and fatty acid metabolism. A consistent nodal protein to these metabolic networks was resistin (upregulated in the good outcome group, p = 0.009). ELISA validation demonstrated resistin to be upregulated in the good outcome group (p = 0.04), irrespective of BMI and ER status. LN involvement was the only covariate with a significant association with resistin measurements (p = 0.004). An ancillary in-silico observation was the induction of the inflammatory response, leucocyte infiltration, lymphocyte migration and recruitment of phagocytes (p < 0.0001, z-score > 2). Survival analysis showed that resistin overexpression was associated with improved DFS. Higher circulating resistin correlated with node-negative patients and longer DFS independent of BMI and ER status in women with EOBC. Overexpression of serum resistin in EOBC may be a surrogate indicator of improved prognosis.

1 February 2001 in Journal of Molecular Biology
Verified
Journal Article
Closed access
KPKathleen Potter
Kathleen Potter
RTRichard K Thomson
Richard K Thomson
AHAngela Hamblin
Angela Hamblin
SRSusan D Richards
Susan D Richards
JLJ.Gordon Lindsay
J.Gordon Lindsay
FSFreda K Stevenson
Freda K Stevenson